Scientific deep-dive
GLP-1s and Fatty Liver: What the Phase 3 Trial Showed
Semaglutide resolved steatohepatitis in 62.9% of patients, against 34.3% on placebo. The difference is 28.7 points. In the one trial in compensated cirrhosis, it produced neither resolution nor fibrosis improvement.
Fatty liver disease is the condition most likely to be sitting underneath a GLP-1 prescription without anyone having mentioned it. In 2025 a phase 3 trial reported that semaglutide resolved steatohepatitis without worsening fibrosis in 62.9% of patients.[1] That figure has been quoted everywhere. The one quoted far less often is the placebo arm: 34.3%.
What the trial found
ESSENCE randomized 1,197 patients with biopsy-confirmed MASH and fibrosis at stage 2 or 3, two to one, to weekly semaglutide 2.4 mg or placebo. It is designed to run 240 weeks. What has been published is a planned interim analysis at week 72, covering the first 800 patients.[1]
| Endpoint | Semaglutide | Placebo | Difference |
|---|---|---|---|
| Steatohepatitis resolved, fibrosis not worse | 62.9% | 34.3% | 28.7 points (95% CI 21.1–36.2) |
| Fibrosis reduced, steatohepatitis not worse | 36.8% | 22.4% | 14.4 points (95% CI 7.5–21.3) |
| Both together | 32.7% | 16.1% | 16.5 points (95% CI 10.2–22.8) |
| Mean body weight change | −10.5% | −2.0% | −8.5 points |
What FDA did with it
FDA acted on this interim result. On August 15, 2025 it approved a new Wegovy indication under its accelerated pathway.[4] The Wegovy injection now carries a label for adults with MASH who have moderate to advanced fibrosis (consistent with stages F2 to F3) but not cirrhosis. Accelerated approval means the license rests on biopsy improvement rather than on liver outcomes, and the label says continued approval may be contingent on a confirmatory trial showing clinical benefit.[3] Heart outcomes are a separate record: an analysis of the SELECT trial found semaglutide cut cardiovascular events in people whose blood tests suggested fibrosis, though the largest of its three figures was the one that missed significance.
Two limits are written into it. The indication belongs to the injection, not to the Wegovy tablets. And it excludes cirrhosis, which matches the evidence set out below.[3] No tirzepatide product is labeled for MASH.[5] Survodutide is not approved for anything. That is why our Wegovy for fatty liver board lists only sellers of the Wegovy pen or injection.
The wider evidence agrees
A 2025 meta-analysis in Liver International pooled 13 phase 2 and phase 3 randomized trials covering 1,811 participants. Among people with MASH and moderate-to-advanced fibrosis, GLP-1 drugs (semaglutide 2.4 mg especially) beat placebo for resolution, with a pooled odds ratio of 3.48, and for fibrosis improvement, at 1.79. Neither estimate showed measurable heterogeneity between trials.[2]
Liver fat measured by MRI fell by a pooled 4.50 percentage points across nine trials, although that estimate varied enormously between studies.[2] Consistency across independent trials is the strongest form this kind of evidence takes, and on the resolution and fibrosis endpoints it is there.
Where it stops working
This matters most to the people with the most at stake, and it rarely makes the coverage. In the same meta-analysis, among people whose MASH had already progressed to compensated cirrhosis, semaglutide produced neither resolution nor fibrosis improvement compared with placebo.[2]
The benefit shows up before cirrhosis. In compensated cirrhosis, the randomized results so far have not shown semaglutide reversing fibrosis.
That finding rests on one small randomized trial, and it is no longer the only one. A phase 2 trial in 457 people with compensated cirrhosis, NCT04971785, posted results on ClinicalTrials.gov in November 2025. At 72 weeks, fibrosis improved without worsening steatohepatitis in 13.7% on semaglutide plus cilofexor and firsocostat against 8.3% on placebo, which missed significance (P = .23). Semaglutide alone reached 15.6%, but the posted results do not test it against placebo. Steatohepatitis did resolve more often on the combination, 57.3% against 22.4% among those with data, a secondary result.[6] So the cirrhosis evidence is a signal rather than a settled answer, and it may change. But it points the same way as most of hepatology: fibrosis becomes progressively harder to reverse the further it has gone, which is the case for acting early.
What this does and does not change for a reader
- If you are on a GLP-1 for weight, this is a plausible bonus and not a treatment plan. MASH is diagnosed by biopsy or by imaging, and nobody can tell you what your liver is doing from your weight.
- The trial population was specific: biopsy-confirmed MASH at fibrosis stage 2 or 3. Results in that group do not automatically describe simple fatty liver without inflammation, which is a different and much more common situation.
- Weight loss and liver improvement traveled together here, with a mean loss of 10.5% against 2.0%.[1] Untangling how much of the liver benefit is the drug and how much is the weight is not something this trial settles, and pooling six biopsy trials does not settle it either, because the link there is driven mostly by bariatric surgery arms.
- It is an interim result. ESSENCE runs to 240 weeks; what has reported is week 72 in the first 800 of 1,197 patients.[1] Long-term outcomes are still an open question.
If liver disease is part of why a GLP-1 was suggested to you, that is a conversation for the clinician holding your imaging and bloodwork. Whether these drugs can themselves injure the liver is a different and much rarer problem, set out in GLP-1 liver damage and liver enzymes. Our evidence-duration piece covers how far the randomized record extends, and the trial tracker follows what is still running, including newer drugs such as survodutide, which pairs GLP-1 with glucagon and is in phase 3 for MASH, and pemvidutide, which uses the same pairing.
Frequently Asked Questions
References
- 1.Sanyal AJ, Newsome PN, Kliers I, et al. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis New England Journal of Medicine. 2025. PMID: 40305708.
- 2.Mantovani A, Morandin R, Fiorio V, et al. Glucagon-Like Peptide-1 Receptor Agonists Improve MASH and Liver Fibrosis: A Meta-Analysis of Randomised Controlled Trials Liver International. 2025. PMID: 40736113.
- 3.Novo Nordisk Pharmaceutical Industries, LP WEGOVY (semaglutide) injection and tablets — prescribing information, SPL version 19 (section 1, Indications and Usage) DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
- 4.U.S. Food and Drug Administration Drugs@FDA: WEGOVY (semaglutide), NDA 215256 — efficacy supplement 024 approved August 15, 2025 FDA Drugs@FDA database. 2025. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215256
- 5.Eli Lilly and Company ZEPBOUND (tirzepatide) injection, for subcutaneous use — prescribing information, SPL version 40 (section 1, Indications and Usage) DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
- 6.Gilead Sciences Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH), NCT04971785, posted results ClinicalTrials.gov. 2025. https://clinicaltrials.gov/study/NCT04971785
Compare the sellers
Related research
Can Ozempic or Mounjaro Cause Liver Damage? Liver Enzymes Evidence Review
Liver injury on semaglutide or tirzepatide is rare. Trial ALT levels fall on average, no label carries a liver warning, and about 31 suspected cases have been published. Gallstones are the likelier cause of a raised liver test, and jaundice or dark urine needs same-day care.
11 min read
Survodutide: What the Phase 3 Evidence Shows
Survodutide, Boehringer Ingelheim's glucagon/GLP-1 dual agonist, cut weight 12.2% to 13.0% at 76 weeks in phase 3, less in type 2 diabetes. About one in five stopped over gut side effects. It is not approved and has no filing date.
9 min read
Does CLA Help With Weight Loss? What the Trials and FDA Records Show
CLA (conjugated linoleic acid) supplements beat placebo by about a third of a kilogram across 70 randomized trials, and not at all for fat in the best-run ones. What the meta-analyses, insulin-resistance trials, liver reports and FDA GRAS letters show.
10 min read
The Biggest Number Is the Weakest
A prespecified SELECT analysis reports cardiovascular reductions of 26%, 21% and 34% across three definitions of liver fibrosis risk. The 34% is the only one that was not statistically significant.
7 min read
The Line Is Drawn by Surgery
A meta-regression found study arms with greater average weight loss had higher rates of fatty liver disease resolving. The authors say plainly it cannot establish cause, and a handful of surgical arms are pulling the line.
6 min read
A Trial About the Measuring Instrument
SAMARA will be reported as showing semaglutide improves fatty liver disease. It was built to ask whether non-invasive tests can replace a biopsy, and the drug was the tool used to answer it.
7 min read
Where to get semaglutide online, safely: sellers our editors have checked
These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
bmiMD
Starting below a standard dose, with microdose tiers
From $129/mo, prepaid
Get started →WellMedRx
Comparing compounded and brand GLP-1 plans with a published state list
From $49/mo
Get started →YourEra
From $99/mo
Get started →